TY - JOUR
T1 - Highlights on Advancing Frontiers in Tissue Engineering
AU - Ashammakhi, Nureddin
AU - Ghavaminejad, Amin
AU - Tutar, Rumeysa
AU - Fricker, Annabelle
AU - Roy, Ipsita
AU - Chatzistavrou, Xanthippi
AU - Hoque Apu, Ehsanul
AU - Nguyen, Kim Lien
AU - Ahsan, Taby
AU - Pountos, Ippokratis
AU - Caterson, Edward J.
N1 - Publisher Copyright:
© 2022, Mary Ann Liebert, Inc.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - The field of tissue engineering continues to advance, sometimes in exponential leaps forward, but also sometimes at a rate that does not fulfill the promise that the field imagined a few decades ago. This review is in part a catalog of success in an effort to inform the process of innovation. Tissue engineering has recruited new technologies and developed new methods for engineering tissue constructs that can be used to mitigate or model disease states for study. Key to this antecedent statement is that the scientific effort must be anchored in the needs of a disease state and be working toward a functional product in regenerative medicine. It is this focus on the wildly important ideas coupled with partnered research efforts within both academia and industry that have shown most translational potential. The field continues to thrive and among the most important recent developments are the use of three-dimensional bioprinting, organ-on-a-chip, and induced pluripotent stem cell technologies that warrant special attention. Developments in the aforementioned areas as well as future directions are highlighted in this article. Although several early efforts have not come to fruition, there are good examples of commercial profitability that merit continued investment in tissue engineering. Tissue engineering led to the development of new methods for regenerative medicine and disease models. Among the most important recent developments in tissue engineering are the use of three-dimensional bioprinting, organ-on-a-chip, and induced pluripotent stem cell technologies. These technologies and an understanding of them will have impact on the success of tissue engineering and its translation to regenerative medicine. Continued investment in tissue engineering will yield products and therapeutics, with both commercial importance and simultaneous disease mitigation.
AB - The field of tissue engineering continues to advance, sometimes in exponential leaps forward, but also sometimes at a rate that does not fulfill the promise that the field imagined a few decades ago. This review is in part a catalog of success in an effort to inform the process of innovation. Tissue engineering has recruited new technologies and developed new methods for engineering tissue constructs that can be used to mitigate or model disease states for study. Key to this antecedent statement is that the scientific effort must be anchored in the needs of a disease state and be working toward a functional product in regenerative medicine. It is this focus on the wildly important ideas coupled with partnered research efforts within both academia and industry that have shown most translational potential. The field continues to thrive and among the most important recent developments are the use of three-dimensional bioprinting, organ-on-a-chip, and induced pluripotent stem cell technologies that warrant special attention. Developments in the aforementioned areas as well as future directions are highlighted in this article. Although several early efforts have not come to fruition, there are good examples of commercial profitability that merit continued investment in tissue engineering. Tissue engineering led to the development of new methods for regenerative medicine and disease models. Among the most important recent developments in tissue engineering are the use of three-dimensional bioprinting, organ-on-a-chip, and induced pluripotent stem cell technologies. These technologies and an understanding of them will have impact on the success of tissue engineering and its translation to regenerative medicine. Continued investment in tissue engineering will yield products and therapeutics, with both commercial importance and simultaneous disease mitigation.
KW - 3D bioprinting
KW - organ-on-a-chip
KW - regenerative medicine
KW - stem cells
KW - tissue engineering
UR - https://www.scopus.com/pages/publications/85113144709
U2 - 10.1089/ten.teb.2021.0012
DO - 10.1089/ten.teb.2021.0012
M3 - Review article
C2 - 34210148
AN - SCOPUS:85113144709
SN - 1937-3368
VL - 28
SP - 633
EP - 664
JO - Tissue Engineering - Part B: Reviews
JF - Tissue Engineering - Part B: Reviews
IS - 3
ER -